Furthermore, CD39, which is defined as a marker of tumor-specific CD8+ T cells in the tumor microenvironment (17), and an effective peptide-induced antitumor response has been reported to be related to activation of CD39+CD8+ T cells in PBMCs of patients with HCC (18). Here, CD8A is linked to neoplasm.